United Kingdom· GB-APID-36584011000001109
Zessly 100mg powder for concentrate for solution for infusion vials
A infliximab product containing infliximab, registered in United Kingdom by Sandoz Ltd. The same ATC class is registered in 14 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Infliximab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AB02 (infliximab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Infliximab · ATC L04AB02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of infliximab costs, country by country.
Normalised to the WHO defined daily dose (3.75 mg), the median price runs from $0.31 in Finland to $24.45 in Switzerland — a ×79 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Infliximab · price per daily dose (3.75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$24.45
- FI Finland$0.31
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Infliximab
- Manufacturer
- Sandoz Ltd
- Country
- United Kingdom (GB)
- ATC code
- L04AB02
- ATC class
- Infliximab
- Defined daily dose
- 3.75 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin05050650961010
- gtin07613421155568
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
443 interactions on record for infliximab.
Graded by severity as the source publishes them — 290 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Infliximab · interactions on record
443 records
- 290 severe
- 146 moderate
- 7 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Infliximab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaFLIXABISamsung Bioepis NL B.V., Delft
- FinlandFlixabiSAMSUNG BIOEPIS NL B.V.
- SpainFLIXABI 100MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONSamsung Bioepis Nl B.V.
- BelgiumFlixabi 100 mgSamsung Bioepis NL
- SwitzerlandFlixabi 100 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungSamsung Bioepis CH GmbH
- IrelandFlixabi 100 mg powder for concentrate for solution for infusionSamsung Bioepis NL B.V.
- IcelandFlixabiSamsung Bioepis NL B.V.
- PolandFlixabiSamsung Bioepis NL B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Remicade, Remsima
- Liechtenstein · Remicade, Remsima
- Norway · Remicade, Remsima
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/de7167ec-9eea-4481-b20f-4cc5f503b73f GET /v1/drugs/de7167ec-9eea-4481-b20f-4cc5f503b73f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "36584011000001109",
"desc": "Zessly 100mg powder for concentrate for solution for infusion vials (Sandoz Ltd)",
"form": "Powder for solution for infusion",
"vpid": "41764711000001106",
"source": "dmd",
"vtm_id": "776332002",
"strength": "100 mg",
"substance": "Infliximab",
"ingredient": "Infliximab",
"supplier_code": "2074301000001102"
}See everything about infliximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.